New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - cilazapril monohydrate 5.22mg equivalent to 5 mg cilazapril base; hydrochlorothiazide 12.5mg - film coated tablet - 5 mg/12.5 mg - active: cilazapril monohydrate 5.22mg equivalent to 5 mg cilazapril base hydrochlorothiazide 12.5mg excipient: hyprolose hypromellose iron oxide red macrogol 8000 maize starch microcrystalline cellulose sodium stearyl fumarate titanium dioxide - apo-cilazapril/hctz is indicated for the treatment of patients with hypertension who are not adequately controlled on monotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - clarithromycin 250mg; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - clarithromycin is indicated for treatment of infections caused by susceptible organisms. such infections include: 1. respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. 2. skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. 3. disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 4. prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - clarithromycin 500mg; clarithromycin 500mg - film coated tablet - 500 mg - active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - clarithromycin is indicated for treatment of infections caused by susceptible organisms. such infections include: 1. respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. 2. skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. 3. disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 4. prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - gabapentin 600mg;   - film coated tablet - 600 mg - active: gabapentin 600mg   excipient: copovidone hyprolose hypromellose macrogol 8000 magnesium stearate titanium dioxide - gabapentin is indicated for the treatment of neuropathic pain in adults over 18 years of age

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - gabapentin 800mg;   - film coated tablet - 800 mg - active: gabapentin 800mg   excipient: copovidone hyprolose hypromellose macrogol 8000 magnesium stearate titanium dioxide - gabapentin is indicated for the treatment of neuropathic pain in adults over 18 years of age

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - imiquimod 12.5mg - topical cream - 5% w/w - active: imiquimod 12.5mg excipient: benzyl alcohol cetyl alcohol glycerol isostearic acid methyl hydroxybenzoate polysorbate 60 propyl hydroxybenzoate purified water sorbitan stearate stearyl alcohol white soft paraffin xanthan gum - indicated for the topical treatment of actinic keratosis on the face and scalp in immunocompetent adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - leflunomide 10mg - tablet - 10 mg - active: leflunomide 10mg excipient: colloidal silicon dioxide crospovidone lactose magnesium stearate - apo-leflunomide is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - leflunomide 20mg - tablet - 20 mg - active: leflunomide 20mg excipient: colloidal silicon dioxide crospovidone lactose magnesium stearate - apo-leflunomide is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - timolol maleate 10mg;  ;  ;   - tablet - 10 mg - active: timolol maleate 10mg       excipient: brilliant blue fcf croscarmellose sodium indigo carmine lactose monohydrate magnesium stearate microcrystalline cellulose - timolol is indicated for patients with: - essential hypertension including the hyperkinetic heart syndrome - the management of atrial fibrillation or flutter. - angina pectoris due to ischaemic heart disease. - prophylaxis of common or classical migraine. - ischaemic heart disease to reduce the risk of cardiac death, including sudden death, and reinfarction in those who have survived the acute phase of myocardial infarction.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ciclopirox 8%{relative} - nail lacquer - 8% w/w - active: ciclopirox 8%{relative} excipient: ethyl acetate gantrez es-435 isopropyl alcohol - apo-ciclopirox is indicated for the topical treatment of fungal infections of the nails, caused by dermatophytes, yeasts or moulds, including tinea pedis, tinea cruris and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum and microsporumcanis, candidiasis due to candida albicans and tinea (pityriasis) versicolor due to malassezia furfur.